AroCell: Redeye resumes coverage following rights issue - Redeye

Redeye resumes its coverage of AroCell following the rights issue adding SEK 86m (before transaction costs) to the company's balance sheet. We adjust our fair value range according to the new number of shares and cash position.

Länk till analysen i sin helhet: https://www.redeye.se/research/833822/arocell-redeye-resumes-coverage-following-rights-issue?utm_source=finwire&utm_medium=RSS